VIATRIS

Viatris is a global pharmaceutical and healthcare company founded in November 2020 by the merger of Mylan and Upjohn, formerly a division of Pfizer. The goal of the establishment was to unite expertise, production capacities, regulatory and commercial opportunities in order to ensure access to high-quality medicines in as many countries as possible.

The name Viatris comes from the Latin words *via* (way) and *tris* (three), and symbolizes three basic ambitions: to expand access to medicines, to lead innovation to meet the needs of patients and to build the trust of the healthcare community around the world.

The company operates in more than 165 countries and territories, with a portfolio of over 1,400 approved molecules. The portfolio includes branded drugs, generic drugs (including "complex generics"), biosimilars, as well as over-the-counter products.

Viatris has an extensive global infrastructure of production and R\&D activities. In Europe, there are multiple production facilities and development centers in countries such as France, Germany, Hungary, Ireland, Italy and the United Kingdom. In addition to Europe, significant centers are in India (Hyderabad) and China (Shanghai), and the company's headquarters is in Canonsburg, Pennsylvania, USA.

In terms of therapeutic areas, Viatris products cover a wide spectrum, including non-infectious and infectious diseases, cardiovascular diseases, endocrinology, diabetes, respiratory disorders, dermatology, women's health, CNS (central nervous system) and gastrointestinal diseases.

The company stands out for its strong focus on drug affordability, business sustainability, and partnerships that enable products and services to reach patients in different countries through the unique Viatris platform called the *Global Healthcare Gateway*.